TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
A study of 575 GLP-1 receptor agonist users found higher reported rates of nail lifting and discoloration than among 1,329 people with obesity or type 2 diabetes who had never used the drugs. The association weakened in adjusted analyses, and an analysis limited to nail problems that began after treatment found no difference between groups; the study does not establish that the medications caused the changes.
A study of 575 people taking GLP-1 receptor agonists found that nail lifting and discoloration were reported more often than among a comparison group of 1,329 people with obesity and/or type 2 diabetes who had never used the drugs. The findings, presented at the European Academy of Dermatology and Venereology meeting in Vienna, show an association—not proof that GLP-1 medications cause nail disorders—and an analysis of newly developed cases found no group difference.
In the unadjusted comparison, 39.3% of GLP-1 users reported onycholysis, the separation of a nail from its nail bed, compared with 8.7% of non-users. That corresponded to a 4.5-fold higher prevalence in the GLP-1 group. Nail discoloration, or dyschromia, was reported by 45.6% of users and 17.0% of non-users, a 2.7-fold difference. Fragile nails and ridges or grooves were also more common among users.
Overall, 66.3% of GLP-1 users reported at least one nail disorder, compared with 52.8% of non-users, a statistically significant difference (P<0.001). Researchers said analyses accounting for factors including age, sex, country and other health conditions still found higher likelihoods of onycholysis and discoloration among users, though the differences were smaller than in the initial comparison. The supplied report does not include all adjusted estimates.
The study recruited participants in France, the United States, Brazil and Mexico. The control group was older on average than the GLP-1 group—56.7 versus 45.3 years—and the sex distribution was about evenly split in both groups. The investigators also examined participants who had lost weight and conducted sensitivity analyses that considered prior nail problems; those analyses continued to show an association. But an analysis restricted to nail changes that began after medication use found no difference in onycholysis or discoloration between the groups.
How the Nail Findings Affect Patients
The results may alert clinicians and patients to nail changes that could otherwise go unmentioned during treatment. Onycholysis can have multiple causes, and the study’s findings do not show that a GLP-1 drug was responsible for an individual patient’s symptoms. Still, the observed frequency supports asking about nail health and whether changes started before or after treatment.
The finding is relevant as GLP-1 receptor agonists are used for conditions including type 2 diabetes and obesity, but the research does not establish a new medication risk or support stopping treatment. Joe Tung, a University of Pittsburgh Medical Center dermatologist who was not involved, told MedPage Today that the findings should not worry people doing well on their medication. He said the results alone would not justify stopping an otherwise beneficial GLP-1 drug prescribed for an appropriate patient.
Tung also noted that rapid weight loss and reduced intake of protein or micronutrients could plausibly affect nails, as weight loss can affect hair. That is a possible explanation, not a mechanism established by this study. Patients who notice nail changes can seek assessment from a dermatologist, who can evaluate common causes and advise on care.
nail health supplements for fragile nails
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What the Study Compared
The research is among the first large-scale analyses of nail and hair effects associated with GLP-1 receptor agonists, according to co-investigator Charles Taieb of European Market Maintenance Assessment. Taieb said nail changes during GLP-1 treatment had previously been reported mainly anecdotally, while cautioning that events occurring during treatment are not necessarily caused by it.
Nearly half of the GLP-1 users in the study reported a history of nail problems before starting treatment. That matters because the main prevalence comparison included existing as well as later-reported conditions. Researchers said sensitivity analyses considering prior problems continued to show differences, but the separate new-onset analysis did not. The study relied on an online survey, and participants’ nails were not examined by dermatologists, according to Tung’s comments to MedPage Today.
Study presenter Bianca Maria Piraccini, of the University of Bologna, said the researchers considered other possible explanations such as trauma and fungal infection. The source report says the investigators ruled these out on the basis that participants did not have active nail disorders when they began treatment; that detail does not resolve whether earlier nail conditions or other differences between groups affected the results.
“These findings alone, however, would not justify stopping an otherwise beneficial GLP-1 medication for the appropriate patient.”
— Joe Tung, University of Pittsburgh Medical Center, speaking to MedPage Today
As an affiliate, we earn on qualifying purchases.
Cause and New Cases Remain Unclear
The study cannot determine whether GLP-1 medicines caused nail disorders. Its most striking figures compare the prevalence of reported problems between groups, but almost half of users said their nail problems predated treatment. In the analysis limited to new-onset nail changes, the difference in onycholysis and discoloration disappeared.
The findings also came from an online survey rather than clinical examinations, and the groups differed in average age. Although researchers adjusted for several health and demographic factors, the available report does not provide every estimate or enough detail to assess all potential sources of bias. Tung said the association shrank after accounting for comorbidities and nutritional deficiencies and noted the absence of dermatologist examinations.
Researchers said they believe the true relationship may lie between the adjusted prevalence findings and the null new-onset comparison. That is an interpretation, not a measured conclusion. Whether the medicines have a direct effect, whether weight or nutrition changes explain some cases, and how often nail symptoms occur after treatment starts all require further study.
nail discoloration treatment products
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Further Research Will Test the Link
Piraccini said the findings will prompt the team to conduct more studies. Further research would need to track nail health before and after treatment, document onset and alternative causes, and assess participants directly rather than relying only on self-reported survey responses. The source material does not give a timetable for that work.
For now, Piraccini advised clinicians to ask about the timing of nail changes and examine affected nails. Tung recommended consulting a dermatologist for new or concerning changes, noting that common nail disorders are often treatable. The study’s results do not establish that patients should change or stop a prescribed GLP-1 medication.
As an affiliate, we earn on qualifying purchases.
Key Questions
What nail changes were associated with GLP-1 use?
The study reported higher rates of onycholysis, or nail separation, and dyschromia, or discoloration, among users. Nail fragility and ridges or grooves were also more common. The study does not prove the drugs caused these changes.
Did the study find that GLP-1 drugs cause nails to detach?
No. It found an association in reported nail problems, but the study design cannot establish cause and effect. When researchers examined only nail changes that began after treatment started, they found no difference in onycholysis or discoloration between users and non-users.
Should someone stop taking a GLP-1 medication because of nail changes?
The study does not support stopping treatment. Joe Tung, who was not involved in the research, told MedPage Today that these findings alone would not justify stopping an otherwise beneficial medication prescribed for an appropriate patient. Patients should discuss treatment decisions with their prescribing clinician.
What should patients do if they notice nail changes?
Patients can tell their clinician when the changes began and whether they were present before treatment. Tung recommended seeing a dermatologist, since common causes of nail disorders can be evaluated and treated.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
